Mercia’s sale of OXGENE has been described by CEO Dr Mark Payton as a ‘transformational event’. It is a great example of how our EIS fund and our PLC’s balance sheet work together to provide superior returns.
Join Dr Mark Payton and Dr Paul Mattick to find out about the OXGENE journey and how its sale reaffirms the significant opportunity and value creation potential offered by Mercia’s ‘fund first’ hybrid investment model which is focused on promising companies located outside of London in what Mercia calls ‘the thriving regions.’